Salta al contenuto principale
Passa alla visualizzazione normale.

GIUSEPPA GRACEFFA

The THYCOVIT (Thyroid Surgery during COVID-19 pandemic in Italy) study: results from a nationwide, multicentric, case-controlled study

  • Autori: Medas, Fabio; Ansaldo, Gian Luca; Avenia, Nicola; Basili, Giancarlo; Boniardi, Marco; Bononi, Marco; Bove, Aldo; Carcoforo, Paolo; Casaril, Andrea; Cavallaro, Giuseppe; Chiofalo, Maria Grazia; Conzo, Giovanni; De Pasquale, Loredana; Del Rio, Paolo; Dionigi, Gianlorenzo; Dobrinja, Chiara; Docimo, Giovanni; Graceffa, Giuseppa; Iacobone, Maurizio; Innaro, Nadia; Lombardi, Celestino Pio; Palestini, Nicola; Pedicini, Francesco; Perigli, Giuliano; Pezzolla, Angela; Scerrino, Gregorio; Spiezia, Stefano; Testini, Mario; Calò, Pietro Giorgio; Calogero, Cipolla
  • Anno di pubblicazione: 2021
  • Tipologia: Articolo in rivista
  • OA Link: http://hdl.handle.net/10447/508688

Abstract

The outbreak of the COVID-19 pandemic has led to a disruption of surgical care. The aim of this multi-centric, retrospective study was to evaluate the impact of the pandemic on surgical activity for thyroid disease among the Italian Units of Endocrine Surgery. Three phases of the pandemic were identified based on the epidemiological situation and the public measures adopted from the Italian Government (1st phase: from 9th March to 3rd May 2020; 2nd phase: from 4th May to 14th June; 3rd phase: from 15th June to 31st). The patients operated upon during these phases were compared to those who underwent surgery during the same period of the previous year. Overall, 3892 patients from 28 Italian endocrine surgical units were included in the study, 1478 (38%) operated upon during COVID-19 pandemic, and 2414 (62%) during the corresponding period of 2019. The decrease in the number of operations was by 64.8%, 44.7% and 5.1% during the three phases of COVID-19 pandemic, compared to 2019, respectively. During the first and the second phases, the surgical activity was dedicated mainly to oncological patients. No differences in post-operative complications were noted between the two periods. Oncological activity for thyroid cancer was adequately maintained during the COVID-19 pandemic.